News for Relay Therapeutics, Inc. (RLAY)

The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Relay Therapeutics (RLAY) Q4 earnings report highlights improved GAAP EPS of -$0.45, surpassing estimates by $0.12.

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastati

Relay Therapeutics Inc (RLAY) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $6.08 million, and the earni

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. ( RLAY), a clinical-stage precision medicine company transforming the drug discov

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Relay Therapeutics Inc (NASDAQ:RLAY) stands against the other...

**media[508686]**

**media[508685]**

Relay Therapeutics officer sells shares worth $345,571

Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock

We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner | Invest. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc.

**media[489238]**

New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patient

**media[487609]**

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential bes

Shares of Dave & Buster’s Entertainment, Inc. PLAY rose sharply in today's pre-market trading after the company posted stronger-than-expected earnings for its...

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday. Shares of Terns Pharmaceuticals, Inc. TERN rose sharply in today's pre-m...

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch